Zenas, a China-US Startup, Breaks Cover with Seven Autoimmune Candidates
March 23, 2021 at 05:58 AM EDT
Zenas BioPharma, a cross-border startup, has in-licensed a portfolio of seven candidates for autoimmune and rare diseases. Zenas, with operations in Hong Kong and Boston , owns worldwide rights to three of its seven pipeline programs. The company claims its expertise in autoimmune diseases helps it to select candidates with best-in-class potential. It plans to use development and commercial strategies to meet patient needs and the requirement for value. Zenas was founded by Tellus BioVentures and Fairmount Funds Management. More details.... Share this with colleagues: // //
